Nanopore sequencing for detecting reciprocal translocation carrier status in preimplantation genetic testing.
Breakpoints
MaReCs
Nanopore sequencing
PGT-SR
Preimplantation genetic testing
Reciprocal translocation
Journal
BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258
Informations de publication
Date de publication:
02 Jan 2023
02 Jan 2023
Historique:
received:
08
05
2022
accepted:
29
12
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
5
1
2023
Statut:
epublish
Résumé
Balanced reciprocal translocation (BRT) is one of the most common chromosomal abnormalities that causes infertility, recurrent miscarriage, and birth defects. Preimplantation genetic testing (PGT) is widely used to select euploid embryos for BRT carriers to increase the chance of a healthy live birth. Several strategies can be used to distinguish reciprocal translocation carrier embryos from those with a normal karyotype; however, these techniques are time-consuming and difficult to implement in clinical laboratories. In this study, nanopore sequencing was performed in two reciprocal translocation carriers, and the results were validated using the next-generation sequencing-based method named, "Mapping Allele with Resolved Carrier Status" (MaReCs). The translocation breakpoints in both reciprocal translocation carriers were accurately identified by nanopore sequencing and were in accordance with the results obtained using MaReCs. More than one euploid non-balanced translocation carrier embryo was identified in both patients. Amniocentesis results revealed normal karyotypes, consistent with the findings by MaReCs and nanopore sequencing. Our results suggest that nanopore sequencing is a powerful strategy for accurately distinguishing non-translocation embryos from translocation carrier embryos and precisely localizing translocation breakpoints, which is essential for PGT and aids in reducing the propagation of reciprocal translocation in the population.
Sections du résumé
BACKGROUND
BACKGROUND
Balanced reciprocal translocation (BRT) is one of the most common chromosomal abnormalities that causes infertility, recurrent miscarriage, and birth defects. Preimplantation genetic testing (PGT) is widely used to select euploid embryos for BRT carriers to increase the chance of a healthy live birth. Several strategies can be used to distinguish reciprocal translocation carrier embryos from those with a normal karyotype; however, these techniques are time-consuming and difficult to implement in clinical laboratories. In this study, nanopore sequencing was performed in two reciprocal translocation carriers, and the results were validated using the next-generation sequencing-based method named, "Mapping Allele with Resolved Carrier Status" (MaReCs).
RESULTS
RESULTS
The translocation breakpoints in both reciprocal translocation carriers were accurately identified by nanopore sequencing and were in accordance with the results obtained using MaReCs. More than one euploid non-balanced translocation carrier embryo was identified in both patients. Amniocentesis results revealed normal karyotypes, consistent with the findings by MaReCs and nanopore sequencing.
CONCLUSION
CONCLUSIONS
Our results suggest that nanopore sequencing is a powerful strategy for accurately distinguishing non-translocation embryos from translocation carrier embryos and precisely localizing translocation breakpoints, which is essential for PGT and aids in reducing the propagation of reciprocal translocation in the population.
Identifiants
pubmed: 36593441
doi: 10.1186/s12864-022-09103-5
pii: 10.1186/s12864-022-09103-5
pmc: PMC9809107
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Informations de copyright
© 2022. The Author(s).
Références
Genomics. 2020 Jan;112(1):494-500
pubmed: 30946890
Hum Reprod. 1997 Sep;12(9):2019-27
pubmed: 9363723
Eur J Obstet Gynecol Reprod Biol. 2018 May;224:66-73
pubmed: 29547808
Ecol Evol. 2021 Dec 07;11(24):18505-18513
pubmed: 35003688
Ceska Gynekol. 2003 Mar;68(2):89-94
pubmed: 12749176
Fertil Steril. 2017 Oct;108(4):620-627.e4
pubmed: 28863935
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8695-E8702
pubmed: 28973897
N Engl J Med. 2020 Jun 18;382(25):2472-2474
pubmed: 32558475
Hum Reprod. 1999 Aug;14(8):2097-101
pubmed: 10438432
J Med Genet. 2019 Nov;56(11):741-749
pubmed: 31439719
Fertil Steril. 2011 Apr;95(5):1606-12.e1-2
pubmed: 21122835
Hum Reprod. 2011 Jul;26(7):1925-35
pubmed: 21489979
J Hum Genet. 2016 Aug;61(8):687-92
pubmed: 27193217
Nat Med. 2009 May;15(5):577-83
pubmed: 19396175
Folia Histochem Cytobiol. 2015;53(2):162-8
pubmed: 26194934
J Soc Gynecol Investig. 2003 Sep;10(6):315-22
pubmed: 12969774
J Assist Reprod Genet. 2016 Aug;33(8):1115-9
pubmed: 27241531
J Med Genet. 2013 Mar;50(3):144-50
pubmed: 23315544
Hum Fertil (Camb). 2001;4(3):168-71
pubmed: 11591275
J Assist Reprod Genet. 2021 Feb;38(2):357-364
pubmed: 33211225
Genom Data. 2014 May 24;2:92-5
pubmed: 26484079
J Assist Reprod Genet. 2020 Mar;37(3):509-516
pubmed: 32026199
Hum Reprod. 2011 Feb;26(2):480-90
pubmed: 21147821
Hum Mutat. 2017 Feb;38(2):180-192
pubmed: 27862604
Genomics Proteomics Bioinformatics. 2016 Oct;14(5):265-279
pubmed: 27646134
Fertil Steril. 2018 Oct;110(5):910-916.e2
pubmed: 30316437
Hereditas. 2018 Sep 28;155:32
pubmed: 30279644
J Assist Reprod Genet. 2012 May;29(5):381-90
pubmed: 22415246
EBioMedicine. 2016 Dec;14:139-147
pubmed: 27840008
Trends Genet. 2015 Oct;31(10):587-599
pubmed: 26209074
Front Genet. 2020 Jan 14;10:1313
pubmed: 32010185